TP-3654 (PIM Inhibitor)

TP-3654 is a second-generation, selective PIM kinase inhibitor.1

PIM as a Potential Target in Cancer and Inflammatory Disorders

PIM kinases are frequently overexpressed in various hematologic and solid tumors, allowing cancer cells to evade apoptosis and promoting tumor growth.2 In inflammatory disorders, PIM-1 kinase has been shown to mediate interleukin-22 signaling in cell-based and animal models.

TP-3654 is an investigational agent and is not approved by the US FDA or any other regulatory authorities.

PIM=proviral integration site for Moloney murine leukemia virus.

References: 1. Foulks JM, Carpenter KJ, Luo B, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014;16(5):403-412. 2. Mondello P, Cuzzocrea S, and Mian M. Pim kinases in hematological malignancies: where are we now and where are we going? J Hematol Oncol. 2014;7:95.

Targeted therapy is at the heart of
our pipeline.

Pipeline >

See why we’re investigating MCL-1
as a potential apoptosis inhibitor.

MCL-1 >

Learn about our clinical trials
currently underway.